Skip to main content


ABCL9.42-0.29 (-2.99%)
BHC25.58-1.02 (-3.83%)
UTHR205.07-6.96 (-3.28%)
DNA5.04-0.26 (-4.91%)
PEN218.65-5.08 (-2.27%)

Company Info

Industry Biotechnology
Sector Health Technology
Employees 206
CEO Dr. Carl Lars G. Hansen
Address 2215 Yukon Street , Vancouver, BC V5Y 0A1
Phone 1.604.559.9005

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Statement Summary

as of 4:00 ET PM 01/18/2022
Total Assets (MRQ) 1.2 B
Total Liabilities (MRQ) 219.3 M
Shareholders’ Equity (MRQ) 953.4 M
Total Revenue (Annual) 5.5 M
Net Income (Annual) -21.4 M

Earnings And Estimates

as of 4:00 ET PM 01/18/2022

Current Qtr EPS Estimate 0.20
Current FY EPS Estimate 0.52
Long Term EPS Growth Estimate 15.00
Next Expected Earnings Date 3/28/2022

ABCL vs S&P 500

as of 01/18/2022
Relative To
S&P 500
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 01/18/2022
Fiscal Quarter Estimate Actual Surprise
09/2021 -0.04 -0.08 +128.57%
06/2021 0.08 -0.01 -112.12%
03/2021 0.36 0.36 -0.45%
12/2020 0.63 0.50 -20.53%

Financial Strength

as of 4:00 ET PM 01/18/2022
Pre-Tax Margin -453.38
Net Margin -1.00
Operating Margin -510.09
Return On Equity 40.38
Return On Assets 32.02
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a


as of 4:00 PM ET 01/18/2022
Price/Earnings (TTM) 12.83
Price/Book (MRQ) 2.96
Price/Cash Flow (TTM) 10.71
Book Value (MRQ) 3.39
Quick Ratio (MRQ) 16.19
Current Ratio (MRQ) 16.22
Total Debt/Equity (MRQ) 0.03

Short Interest

as of 1:35 PM ET 01/19/2022
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00




Balance Sheet

Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00


EBT Excluding Unusual Items


Income Statement

Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Dividends Paid Per Share 0,0.00




Cash Flow Statement

Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 01/18/2022
Current Qtr
Next Qtr
Consensus Estimate $0.20 $0.09
# of Estimates 6 2
High Estimate $0.24 $0.12
Low Estimate $0.10 $0.06
Year Ago EPS $0.43 $0.43
Year Over Year Growth Estimate -53.48% -79.29%
Current Yr
Next Yr
Consensus Estimate $0.52 $-0.02
# of Estimates 8 8
High Estimate $0.61 $0.16
Low Estimate $0.40 $-0.25
Year Ago EPS $0.43 $0.52
Year Over Year Growth Estimate 21.51% -104.02%
Current Qtr
Next Qtr
Current Year
Next Year
Consensus Estimate $0.20 $0.09 $0.52 $-0.02
# of Estimates 6 2 8 8
High Estimate $0.24 $0.12 $0.61 $0.16
Low Estimate $0.10 $0.06 $0.40 $-0.25
Year Ago EPS $0.43 $0.43 $0.43 $0.52
Year Over Year Growth Estimate -53.48% -79.29% 21.51% -104.02%

Insider Information Summary

as of 12/31/1969
% Insiders - 40.70%
% Remaining Total Shares - 59.30%
Current 1 Month
Net Insider Transaction 1.42 M 1.42 M
Shares Bought 1.42 M 1.72 M
Shares Sold 0.00 300.00 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings


Recent Articles from TheStreet

China Looks To Disney To Help Improve Ties With The US

Here's Credit Suisse's List of Stocks Boosted by Inflation

Credit Suisse Wednesday published a list of the S&P 500 stocks it views as benefiting most from inflation.

Inflation History thumb

The Feds Monetary Policy Will Hit Stocks and Bonds, Analyst Says

Jim Bianco says financial tightening from the Fed will hit bond and stock markets.

Robert Powell Federal Reserve Chairman Lead

Investors Dislike Fed's Two Potential Moves

The Federal Reserve is planning to reduce its balance sheet and raise interest rates in 2022, which could increase the dips in both the stock and bond markets.

Starbucks Pumpkin Spice Latte Lead

Starbucks Drops Vaccine Mandate In Wake Of Supreme Court Ruling

The coffee chain will now encourage, but not demand, that employees get the vaccine.

Marc Andreessen and Jack Dorsey Lead

Jack Dorsey And Marc Andreessen Can't Stop Sparring Over Web3

"As my first act as Chairman, the World Economic Forum is hereby renamed Wef3," Andreessen wrote on Twitter.


Apple, Amazon, Disney Could Snatch Up Game Makers EA, Take-Two

Microsoft paid a hefty premium for Activision, making rivals in the space attractive to investors.

Hong Kong Property Stocks Enjoy Value Revival As They Hitch Ride On Economic Rebound With Foreign Funds On The Prowl

Value Vaulted to 'Early Lead' in 2022

With the Fed getting more aggressive, value stocks may finally be getting their due.

Movie Director Lead

Crypto Looks for Starring Role in Movie Business

Cryptocurrency and NFTs offer filmmakers an innovative way to finance their work, analysts say.

CVS Lead

CVS Stock is a Good Hideout During Volatility

Recently raised guidance and a decent dividend offer investors a safe harbor for now, Real Money's Stephen 'Sarge' Guilfoyle says.

Cathie Wood Lead

Cathie Wood's Ark ETFs Continue to Lose Ground

The flagship Ark Innovation ETF’s share-price gain isn’t much ahead of the S&P 500’s gain for the past two years--43% to 38%.